Xeloda (zah-LOE-duh, capecitabine), the first ORAL drug for metastatic breast cancer

Roche is now marketing Xeloda (zah-LOE-duh, capecitabine),the first ORAL drug for metastatic breast cancer.

It's for patients who can't take, or are resistant to, treatmentwith paclitaxel (Taxol) and anthracyclines (Adriamycin, etc).

Xeloda is a prodrug of 5-FU (5-fluorouracil). It'smetabolized to 5-FU by enzymes in tumor cells.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote